Abstract
Choline Kinase (ChoK) comprises a family of cytosolic enzymes involved in the synthesis of phosphatidylcholine (PC), the most abundant phospholipid in eukaryotic cell membranes. One of the ChoK isoforms, Choline Kinase α (ChoKα), is found over expressed in human tumours. Chemical inhibitors able to interfere with ChoK activity have proven to be effective antitumoral drugs in vitro and in vivo. To validate the use of selective ChoKα inhibitors in cancer therapy, we have developed a genetic strategy to interfere specifically with ChoKα activity based on the generation of a shRNA against the alpha isoform of ChoK. Here we demonstrate that specific inhibition of ChoKα by shRNA has antitumor activity. The specific depletion of ChoKα induces apoptosis in several tumor-derived cell lines from breast, bladder, lung and cervix carcinoma tumors, while the viability of normal primary cells is not affected. Furthermore, this selective antiproliferative effect is achieved both under in vitro and in vivo conditions, as demonstrated by an inducible ChoKα suppression system in human tumour xenografts. These results demonstrate that ChoKα inhibition is a useful antitumoral strategy per se, and provides definitive and non-ambiguous evidence that ChoKα can be used as an efficient and selective drug target for cancer therapy.
Keywords: Choline Kinase, anticancer drugs, target validation, apoptosis, ChoK Inhibitors, shRNA
Current Cancer Drug Targets
Title: Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Volume: 8 Issue: 8
Author(s): Monica Banez-Coronel, Ana Ramirez de Molina, Agustin Rodriguez-Gonzalez, Jacinto Sarmentero, Mª Angeles Ramos, Miguel Angel Garcia-Cabezas, Lourdes Garcia-Oroz and Juan Carlos Lacal
Affiliation:
Keywords: Choline Kinase, anticancer drugs, target validation, apoptosis, ChoK Inhibitors, shRNA
Abstract: Choline Kinase (ChoK) comprises a family of cytosolic enzymes involved in the synthesis of phosphatidylcholine (PC), the most abundant phospholipid in eukaryotic cell membranes. One of the ChoK isoforms, Choline Kinase α (ChoKα), is found over expressed in human tumours. Chemical inhibitors able to interfere with ChoK activity have proven to be effective antitumoral drugs in vitro and in vivo. To validate the use of selective ChoKα inhibitors in cancer therapy, we have developed a genetic strategy to interfere specifically with ChoKα activity based on the generation of a shRNA against the alpha isoform of ChoK. Here we demonstrate that specific inhibition of ChoKα by shRNA has antitumor activity. The specific depletion of ChoKα induces apoptosis in several tumor-derived cell lines from breast, bladder, lung and cervix carcinoma tumors, while the viability of normal primary cells is not affected. Furthermore, this selective antiproliferative effect is achieved both under in vitro and in vivo conditions, as demonstrated by an inducible ChoKα suppression system in human tumour xenografts. These results demonstrate that ChoKα inhibition is a useful antitumoral strategy per se, and provides definitive and non-ambiguous evidence that ChoKα can be used as an efficient and selective drug target for cancer therapy.
Export Options
About this article
Cite this article as:
Banez-Coronel Monica, de Molina Ramirez Ana, Rodriguez-Gonzalez Agustin, Sarmentero Jacinto, Ramos Angeles Mª, Garcia-Cabezas Angel Miguel, Garcia-Oroz Lourdes and Lacal Carlos Juan, Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733432
DOI https://dx.doi.org/10.2174/156800908786733432 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids Health Benefits and Their Molecular Mechanism
Mini-Reviews in Medicinal Chemistry Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer: Update
Medicinal Chemistry Reviews - Online (Discontinued) Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Withdrawal Notice: EnzyPha, an Engineered Helper Phage Developed to Overcome Most of the Limitations Regarding Filamentous Phage Titration and ELISA Tests
Protein & Peptide Letters The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry Local Gene Delivery for Cancer Therapy
Current Gene Therapy Purification and Characterization of a Lectin from the Indian Cultivar of French Bean Seeds
Protein & Peptide Letters Chemo-drug Controlled-release Strategies of Nanocarrier in the Development of Cancer Therapeutics
Current Medicinal Chemistry Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Insights into the Platelet Releasate
Current Pharmaceutical Design Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients
Current Pharmacogenomics and Personalized Medicine Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Protein Misfolding in Conformational Disorders: Rescue of Folding Defects and Chemical Chaperoning
Mini-Reviews in Medicinal Chemistry The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets